重大事件
即時報告
8-K
2026-06-26
Anavex Life Sciences 確定2026年度股東大會於9月24日舉行 股東提案截止日為7月10日
AI 繁中摘要
Anavex Life Sciences Corp. 於 2026 年 6 月 25 日提交 8-K 表格，宣布董事會已正式確定 2026 年度股東大會將於 2026 年 9 月 24 日舉行，並設定 2026 年 7 月 31 日為股東登記日，以決定有權獲悉大會通知及投票的股東名單。由於本次年會日期較 2025 年年會週年日延後超過 30 天，公司按《1934 年證券交易法》Rule 14a-5(f) 規定，為股東提案及董事提名設立修訂截止期限。
任何擬根據 Rule 14a-8 納入公司委託書材料的股東提案，以及所有不經 Rule 14a-8 提交的股東提案或董事提名，必須於 2026 年 7 月 10 日或之前送達公司主要行政辦公室（地址：紐約市第五大道 630 號 20 樓，郵編 10111），公司方視為在合理時間內收到，以便於印刷及寄發委託書材料前處理。
📅 對投資者的影響：若股東有意提交提案或提名董事人選，須嚴格遵守此提前截止日期，逾期提交將不被接納。建議相關股東立即著手準備並預留郵遞時間，確保合規。年會具體時間、地點及其他詳情將在後續的正式委託書聲明中公布。
展開英文正文
false 0001314052 0001314052 2026-06-25 2026-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2026 ANAVEX LIFE SCIENCES CORP. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37606 98-0608404 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 630 5th Avenue, 20th Floor New York, NY USA 10111 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: 1-844-689-3939 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AVXL Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01. Other Events. On June 25, 2026, the Board of Directors (the “Board”) of Anavex Life Sciences Corp. (the “Company”) established September 24, 2026, as the date of the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) and July 31, 2026, as the record date for the determination of stockholders entitled to notice of and to vote at the 2026 Annual Meeting. The time, location and additional details for the 2026 Annual Meeting will be set forth in the Company’s definitive proxy statement for the 2026 Annual Meeting. As the date of the 2026 Annual Meeting will be more than 30 days after the anniversary of the Company’s 2025 Annual Meeting of Stockholders, the Company is providing notice of the revised deadlines for submission of any qualified stockholder proposal or qualified stockholder nomination in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). For the 2026 Annual Meeting, (a) any stockholder proposal submitted for inclusion in the Company’s proxy materials pursuant to Rule 14a-8 under the Exchange Act (“Rule 14a-8”) and (b) any stockholder proposal or director nomination submitted outside of Rule 14a-8, must be received by the Company at its principal executive offices at the following address, Anavex Life Sciences Corp., 630 5th Avenue, 20th Floor, New York, NY 10111, a reasonable time before the Company begins to print and send its proxy materials. The Company will consider proposals and director nominations received on or before July 10, 2026, to be received within a reasonable time before the Company begins to print and send its proxy materials. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANAVEX LIFE SCIENCES CORP. Date: June 26, 2026 By: /s/ Sandra Boenisch Sandra Boenisch, CPA, CGA Principal Financial Officer, Treasurer